Literature DB >> 10526289

Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.

H M Brown1, R A Komorowski, S D Wilson, M J Demeure, Y R Zhu.   

Abstract

BACKGROUND: In the absence of metastases, there are no reliable microscopic features that distinguish malignant from benign pheochromocytomas. Because a common feature of malignancy is the loss of cell cycle regulation and normal growth arrest, the authors hypothesized that analysis of the cell cycle could be used to aid in the diagnosis of malignant pheochromocytoma.
METHODS: Cell cycle analysis of archival samples of 51 pheochromocytomas (40 sporadic, 11 familial) from 45 patients, including 6 malignant and 45 benign tumors, was conducted. Flow cytometry data and immunohistochemistry for markers of cell proliferation (proliferating cell nuclear antigen [PCNA] and MIB-1 [Ki-67]) were correlated with the authors' clinical data base records, with a mean follow-up of 66 months.
RESULTS: No correlation of DNA ploidy, S-phase fraction by flow cytometry, or PCNA with malignancy was observed. Staining for the MIB-1 nuclear proliferation marker was positive in 3 of 6 (50%) of the malignant pheochromocytomas and negative in all 45 benign tumors (P< 0.01).
CONCLUSIONS: Contrary to some previous reports, a diploid DNA pattern does not necessarily predict benign behavior of pheochromocytoma. In this study, cell cycle analysis and, in particular, assessment of the MIB-1 nuclear proliferation marker was useful in the histologic evaluation of pheochromocytoma, as MIB-1 was expressed only in malignant tumors. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10526289

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Malignant pheochromocytoma: new malignancy criteria.

Authors:  Pierre de Wailly; Luigi Oragano; Francois Radé; Anthony Beaulieu; Vincent Arnault; Pierre Levillain; Jean Louis Kraimps
Journal:  Langenbecks Arch Surg       Date:  2011-11-09       Impact factor: 3.445

Review 2.  Differential diagnosis of pheochromocytomas and paragangliomas.

Authors:  A M McNichol
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Sporadic type composite pheochromocytoma with neuroblastoma: clinicomorphologic, DNA content and ret gene analysis.

Authors:  F A Candanedo-González; I Alvarado-Cabrero; A Gamboa-Domínguez; A Cérbulo-Vázquez; R López-Romero; L Bornstein-Quevedo; M Salcedo-Vargas
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  A Case of Malignant Pheochromocytoma Presenting 7 Years After the Initial Surgery.

Authors:  Larsa Al-Omaishi; Jonathan Babin; Ralph L Corsetti
Journal:  Ochsner J       Date:  2017

Review 5.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

6.  18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.

Authors:  Elise M Blanchet; David Taieb; Corina Millo; Victoria Martucci; Clara C Chen; Maria Merino; Peter Herscovitch; Karel Pacak
Journal:  J Nucl Med       Date:  2015-09-10       Impact factor: 10.057

7.  Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.

Authors:  Nobue Kumaki; Hiroshi Kajiwara; Kaori Kameyama; Ronald A DeLellis; Sylvia L Asa; R Yoshiyuki Osamura; Hiroshi Takami
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 8.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 9.  Adrenal tumors: how to establish malignancy ?

Authors:  M Fassnacht; W Kenn; B Allolio
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

Review 10.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.